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ABSTRACT 
Objective: Carvedilol (CRV) is a beta blocker drug that is basically used for the treatment of hypertension, heart failure and arrhythmias. The 
objective of this study is to increase the oral bioavailability of CRV by using solid dispersions to enhance its solubility and dissolution rate.  
Methods: Various preparations of CRV-solid dispersions (SDs) and physical mixtures (PMs) were prepared using different carriers; polyethylene 
glycol (PEG) 4000, polyvinyl pyrrolidone (PVP) K30 and tartaric acid. Effect of type and concentrations of carriers on solubility and dissolution of 
CRV were studied. Selected CRV-SDs and PMs that showed the best solubility and dissolution were exposed for further investigations e. g. Fourier 
Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC) and X-ray diffraction (XRD). In addition, the oral antihypertensive 
activity of the optimized formula compared to pure CRV was evaluated in induced hypertensive adult albino male rats. 
Results: All carriers enhanced the dissolution rate of CRV. Tartaric acid had the most persuasive effect on the rate and the extent of dissolution of 
CRV, followed by PEG4000 and PVP. FTIR, DSC and XRD diffraction revealed an interaction between CRV and tartaric acid with the possibility of a 
polymorphic change in CRV. The optimized formula CRV-tartaric acid (SD 1:0.3) causes a marked increase in the antihypertensive activity compared 
to pure CRV. 
Conclusion: Tartaric acid is a promising and efficient carrier for improving the solubility, dissolution and oral bioavailability of CRV. 
Keywords: Carvedilol, Solid dispersion, Physical mixture, Hypertension, Oral bioavailability 
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INTRODUCTION 
Therapeutic effectiveness of a drug depends on upon the 
bioavailability and the solubility of drug molecules. The poor 
solubility and low dissolution rate of poorly water-soluble drugs in 
the aqueous gastrointestinal fluids often causes insufficient 
bioavailability. Therefore, it is necessary to enhance dissolution of 
these drugs to ensure maximum therapeutic utility [1].  
The most promising method for promoting dissolution is the 
formation of a solid dispersion in a proper carrier. The solid 
dispersion reduces particle size and therefore increases the 
dissolution rate and absorption of drugs. The term “solid dispersion” 
refers to the dispersion of one or more active ingredients in an inert 
carrier in a solid state, frequently prepared by the melting (fusion) 
method, a solvent method, or fusion solvent-method [2, 3]. 
Carriers commonly used in solid dispersions (SDs) are PEG's of high 
molecular weight, polyvinyl pyrrolidones, urea, cyclodextrins, 
sugars, cellulose derivative and others [4, 5]. 
Carvedilol (CRV) ((±)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxy-
phenoxy) ethyl] amino]-2-propanol) is a beta-blocker used to treat 
high blood pressure and heart failure. CRV is practically insoluble in 
water and exhibits pH dependent solubility. The solubility of CRV is 
limited because of its protonation, resulting in situ hydrochloride 
salt formation which exhibits less solubility in acidic medium [6]. 
Many studies showed significant enhancement in the solubility of 
CRV by using solid dispersions, for example; Cyclodextrins [7], 
Gelucire 50/13 [8], PVP K30 [9] and Poloxamer 188 [10]. 
Most of the previous literature on CRV concerned with the in vitro 
study, and nearly none of them give an interest with studying oral 
bioavailability of the CRV-SDs.  
The Aim of the present work was to enhance aqueous solubility of 
CRV by solid dispersion technique using carriers such as PEG 
4000, polyvinylpyrrolidone PVP K30 and tartaric acid. Effect of 
variables e.g. type and concentration of carriers will be studied. 
The carrier that showed highest solubility and dissolution of CRV 
would be exposed to further investigations e. g. FTIR, DSC and 
XRD. Oral bioavailability of the optimized formula of the selected 
carrier of CRV SDs would be evaluated by measuring the 
antihypertensive activity in induced hypertensive adult albino 
male rats. 
MATERIALS AND METHODS 
Materials  
CRV (kindly supplied by Amoun Co., Egypt), Methanol, polyethylene 
glycol (PEG) 4000, polyvinyl pyrrolidone (PVP) K30 and tartaric acid 
(kindly supplied by Nasr Pharmaceuticals Chemicals Co., Egypt). All 
other chemicals were of analytical grade. 
Solubility studies 
Solubility studies were carried out according to the method of 
Higuchi and Connors, 1965 [11]. An excess of CRV (10 mg) was 
placed into 25-ml glass vial containing various concentrations of 
each carrier in 10 ml distilled water. All glass vials were closed with 
stopper and cover sealed with cellophane to avoid solvent loss. The 
content of the suspension was equilibrated by shaking in a 
thermostatically controlled water bath at 25 o
After attainment, the equilibrium, the content of each vial was then 
filtered through a double filter paper (Whatman 42). The filtrate was 
suitably diluted and assayed spectrophotometrically at 242 nm to 
measure the amount of dissolved drug. There was no interference 
from all used carriers at this wavelength. The solubility of CRV in 
water at the same temperature was also determined following the 
same procedure mentioned above [12]. 
C for 24 h.  
Preparation of physical mixtures (PMs) 
Physical mixtures (PMs) were prepared by triturating appropriate 
quantities of CRV and carriers using a mortar and pestle and then 
transferred to a vacuum desiccator until use [9]. 
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Preparation of solid dispersions by solvent evaporation method 
The solid dispersion of CRV using (PEG) 4000, (PVP) K30 and tartaric 
acid were prepared by dissolving CRV and weighed carrier 
corresponding to the chosen ratio in methanol (table 1). The solution 
was stirred at room temperature and methanol was then removed 
under vacuum at a maximum temperature of 40 o
The dried mass of PMs and SDs was pulverized and passed through 
355 μm sieve. The powder was dried at 40 
C. The solid residue 
was dried in a vacuum oven for 24 h at room temperature [13].  
o
 
C for 3hs in a tray drier, 
and then the powder was stored in a desiccator for further studies.
Table 1: Types of carriers and their ratios in CRV solid dispersions and physical mixtures 
Carrier Drug: Carrier W/W 
Polyethylene glycol (PEG) 4000 1:1, 1:3 and 1:5 
Tartaric acid 1:0.1, 1:0.2 and 1:0.3 
polyvinyl pyrrolidone (PVP) K30 1:0.5, 1:1, 1:2 and 1:3 
 
In vitro dissolution studies 
The dissolution of CRV from the prepared (SDs) and (PMs) was 
carried out according to the USP-24 rotating paddle method [13]. 
Dissolution medium consisting of 200 ml of distilled water was used. 
The reason for choosing distilled water as the dissolution medium is 
that CRV has a low solubility in water than in acidic or basic media 
[14]. The stirring rate was 100 rpm and the temperature was 
maintained at 37±0.5 PoPC. A sample of 10 mg of CRV or its equivalent 
of the (SDs) or the (PMs) was placed on the surface of the 
dissolution medium. At appropriate time intervals (5, 10, 20, 30, 45, 
60, 90 and 120 min.), 5 ml samples were withdrawn and replaced 
with an equivalent amount of the fresh dissolution medium kept at 
37 PoPC. The samples were filtered rapidly through a double layered 
filter paper (Whatman 42), diluted with dissolution medium and 
assayed spectrophotometrically at λRmaxR (242 nm) without 
interference from the carriers.  
The amount of CRV dissolved at different time intervals was 
calculated using a standard calibration curve developed in the same 
medium. Each experiment was carried out in triplicate. 
A cumulative correction factor was applied to compensate for the 
previously withdrawn samples according to the following equation [15]:  
CRnR = CRn obsR+(5/865) CRn-1 
Where:  
CRn obsR:R Robserved concentration of nPthP sample 
CRn-1:R concentration of nPthP sample 
CRn: Rcorrected concentration of nPthP sample 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra were obtained on a Perkin-Elmer 1600 FTIR 
spectrophotometer using KBr disk method. The scanning range was 
400–4000 cmP-1P and the resolution was 1 cmP-1P. 
Differential scanning calorimetry (DSC) 
The DSC thermograms were recorded on a Shimadzu-DSC 50. 
Samples (2.5 mg) were heated in hermetically sealed aluminium 
pans over the temperature of 30-300 PoPC at a constant rate of 10 
P
o
PC/min under a nitrogen purge (30 ml/min). 
X-ray diffraction (XRD) 
X-ray diffraction patterns were obtained using a Siemens Kristallofex 
D-5000 powder diffractometer with CuKα radiation. Diffractograms 
were run at a scanning speed of 8PoP/min the 2ϴ of 0-80PoP. 
In vivo study 
Calculated amount of either CRV powder or solid dispersion (CRV–
tartaric acid 1:0.3 w/w) was suspended in 2% gum mucilage. Adult 
albino male rats weighing (200~250 gm) were used. Rats were 
obtained from animal breeding center, Faculty of Veterinary 
Medicine, Zagazig University, Egypt and treated according to Ethical 
Committee of animal handling in faculty of pharmacy Zagazig 
University “ECAHZU” 
All groups (table 2) received an equivalent of 12 mg CRV per kg body 
weight of rats [16]. 
  
Table 2: Animals groups and route of administration 
Group No. Received formulation 
Group I (control): rats were subjected to operation but not received any drug 
Group II CRV alone 
Group III Solid dispersion (CRV–tartaric acid 1:0.3 w/w) 
 
Induction of hypertension 
The rats were anesthetized with urethane (ethyl carbamate) in a 
dose of 2.0 gm/kg body weight which was injected I.P as 25% 
freshly prepared aqueous solution [17]. 
After shaving of hair and sterilization of skin, 2 cm long incisions was 
made in the left side just below the ribs and 0.5 cm away from the 
vertebral column. The left renal artery was exposed and completely 
ligated with 4-0 sterile surgical silk as close as possible to the aorta. The 
incision was closed by careful continuous suturing of the muscle layer of 
4-0 silk with a non-cutting needle; then the skin was approximated and 
closed with interrupted sterile surgical 0-silk sutures (fig. 1). 
Postoperatively, the rats were given penicillin G (100,000 units I. 
M) per rat for 3 successive days; and were allowed free access to 
food and water for 28 d. The rats were anesthetized again as 
before and the blood pressure of rats was determined employing 
the method of Parasuraman and Raveendran, 2012 and Zheng et 
al., 2008 [17, 18]. 
 
Fig. 1: Exposed left renal artery 
 
Statistical analysis 
Two-way analysis of variance (ANOVA) was employed to assess the 
significance difference between the formulations using GraphPad 
Prism version 5.04 (Windows, GraphPad software, San Diego, CA). p 
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Values of >0.05, >0.01 and >0.001 will be considered statistically 
significant, highly significant and very highly significant, respectively. 
RESULTS AND DISCUSSION 
Effect of different carriers on the solubility of CRV 
In the present study, the solubility of CRV in distilled water at 25 o
Table 3, summarizes the effect of various carriers on the solubility of 
CRV in distilled water. In the case of tartaric acid, PVP and PEG 4000, 
the solubility of CRV linearly increased as the carrier concentration 
increased, showing the feature of an A
C 
was found to be 0.013 mg/ml, a finding that is approximately half 
the value (0.028 mg/ml) reported by Rehab et al., 2013 [19]. 
L
These carrierse arranged descendingly according to their effect on 
increasing the solubility of CRV as tartaric acid>PVP>PEG 4000. The 
increased solubility of CRV in carrier's solution may be attributed to 
both complex formation and reduction in interfacial tension of water 
and hence intermolecular forces and polarity occurred by the 
presence of these carriers [21]. 
-type solubility phase 
diagram [12]. This illustrates that a complex may be formed which is 
soluble and did not form a precipitate over the range of carrier 
concentration. These results are in agreement with Navneet et al., 
2015 [20] who stated that the solubility of glibenclamide linearly 
increased as the carrier concentration (PEG 4000) increased.  
  
Table 3: Solubility enhancement data of CRV in various carrier solutions at 25 o
Item 
C 
Phase solubility diagram Optimum carrier concentration (%) Solubility (mg/ml) Solubility factor  
CRV A --------- L 0.013±0.001 -------- 
Tartaric acid A 0.057 L 1.161±0.03 89.3 
PVP A 10 L 0.1652±0.01 12.70 
PEG 4000 A 10 L 0.0433±0.003 3.33 
Solubility factor = (total solubility/intrinsic solubility), AL
 
Dissolution studies 
The dissolution profiles of pure CRV and SDs with different carriers 
are shown in table 4. The shapes of the dissolution profiles were 
examined using the following parameters:  
= type of phase solubility diagram, Mean of solubility±SD (n=3). 
I) The initial dissolution rate (IDR) calculated as percent dissolved 
of the drug over the first 20 min per minute. 
II) The percentage of the drug dissolved after 20, 60 and 120 min 
(PD20,  PD60and PD120
III) The dissolution efficiency (DE %) parameter after 120 min 
(enhancement factor) [22, 23]. 
). 
The dissolution efficiency can be defined as the area under the curve 
up to a certain time. It is measured using the trapezoidal method by 
certain equation through Microsoft office Exell and is expressed as 
=(b1+b2)/3*(a2-a1)  
The dissolution efficiency (enhancement factor) is expressed as  
(AUC a/AUC b) where a is PM or SD, b is pure drug 
The calculated dissolution parameters revealed that at 120 min pure 
CRV yielded the slowest dissolution rate with only about 7.8% of the 
drug is dissolved. The hydrophobic property of CRV prevented its 
contact with the dissolution medium which led to a slow dissolution 
rate [24]. 
As shown in table 4, all (PMs) showed higher dissolution rate than 
pure CRV as reflected by higher (IDR) and greater extent of 
dissolution after 60 min. These results can be explained on the basis 
that the dry mixing brings the drug in close contact with the 
hydrophilic polymer [25].  
It is also apparent that the rate and the extent of dissolution of CRV 
from (SDs) exceeded those of pure CRV. The PD120 
 
was 91.42 %, 
25.46 %, 17.55 % and 7.8 % for tartaric acid (1:0.3), PEG4000 (1: 3), 
PVP K30 (1:3) CRV-SDs and pure drug, respectively. Their 
enhancement factor was 1473.7, 369.5, 257.4 and 100. 
Table 4: Dissolution parameters of CRV in distilled water from different CRV–tartaric acid, PEG 4000 and PVP K30 systems 
Composition (w/w) IDR (% dissolved/min) PD20 (%) PD60 (%) PD120 (%) Enhancement factor 
CRV Powder 0.23±0.01 4.69±0.3 5.39±0.96 7.8±0.4 100 
CRV-to-D-tartaric acid      
PM 1:0.1 1.22±0.07 24.5±1.49 36.6±0.91 42.25±0.73 615.19 
SD 1:0.1 2.12±0.01 42.47±0.38 49.26±0.65 53.43±0.54 841.3 
PM 1:0.2 1.5±0.01 30.12±0.30 44.3±0.82 48.36±2.32 686.2 
SD 1:0.2 2.43±0.08 48.62±1.66 56.18±2 59.22±1.86 956 
PM 1:0.3 1.95±0.09 39.11±1.94 50.26±0.56 58.93±1.15 853.7 
SD 1:0.3 3.52±0.17 70.75±3.54 87.11.68±3.6 91.42±4.61 1473.7 
CRV-to-PEG 4000      
PM 1:1 0.38±0.02 7.63±0.26 11.74±0.68 14.67±0.03 199.2 
SD 1:1 0.51±0.08 10.52±1.96 14.58±1.58 19.77±0.07 263 
PM 1:3 0.67±0.02 13.57±0.48 17.13±0.71 18.89±2.46 287.1 
SD 1:3 0.86±0.01 17.2±0.28 21.5±0.69 25.46±0.03 369.5 
PM 1:5 0.6±0.04 12.06±0.99 51.43±0.69 18.20±0.09 266.5 
SD 1:5 0.67±0.05 13.41±1.18 16.79±1.6 18.33±0.1 288.9 
CRV-to-PVP K30      
PM 1:0.5 0.47±0.009 9.5±0.19 12.68±0.5 14.54±0.58 213.1 
SD 1:0.5 0.6±0.01 12.11±0.25 15.64±0.24 18.35±0.53 266.7 
PM 1:1 0.43±0.01 8.77±0.3 11.26±0.2 12.65±0.43 190.3 
SD 1:1 0.74±0.02 14.83±0.46 17.9±0.37 21±0.94 310.1 
PM 1:2 0.45±0.008 9.06±0.17 11.13±0.12 12.32±0.31 189.8 
SD 1:2 0.55±0.01 11.15±0.21 41.32±0.3 17.90±0.41 251.5 
PM 1:3 0.46±0.02 9.16±0.47 11.01±0.17 11.75±0.2 187.9 
SD 1:3 0.57±0.005 11.38±0.1 14.68±0.59 17.55±0.64 257.4 
IDR = Initial dissolution rate, PD20, PD60, PD120 = Extent of dissolution after 20, 60, 120 min, DE = Dissolution efficiency (enhancement factor) 
after 120 min=AUC a/AUC b, (a: PM or SD, b: pure drug), mean±SD (n=3). 
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The main possibilities for improving dissolution according to this 
analysis are to increase the surface area available for dissolution by 
decreasing the particle size of the solid compound and/or by 
optimizing the wetting characteristics of the compound surface, to 
decrease the boundary layer thickness and to improve the apparent 
solubility of the drug [26-28].  Tartaric acid had the most influential 
effect on the rate and the extent of dissolution of CRV. It was found to 
decrease the pH of the solution, thus enhancing CRV solubility [26].  
PEG showed increase in drug dissolution behavior due to an increase in 
the drug solubility by its entrapment in the helical interstitial space of 
PEG molecules [29,30], On the other side, PVP showed increase in drug 
dissolution by drug incorporation into its linear chain, thus retarding the 
crystallization of poorly water soluble drug [30, 31]. 
The carrier concentration was found to play a significant role in the 
solubility and the dissolution of dispersions, particularly with 
tartaric acid. As regard to tartaric acid SDs, it was observed that 
peak solubility increased and time is taken to achieve this peak 
decreased on increasing concentration of tartaric acid. In addition, 
pH values were dependent on the concentration of tartaric acid. A 
marginal change in pH may be sufficient to influence the solubility of 
CRV owing to its strong pH-dependent solubility [26].  
PEG4000 and PVP also demonstrated an increased dissolution as the 
proportion of the polymer increased. This is in agreement with that 
reported by Kumar et al., 2011 and Mudgal and Pancholi, 2012 [31, 32] 
Hence, tartaric acid SDs showed the highest solubilization and the 
most powerful effect on the rate and the extent of dissolution of CRV. 
It is selected for further investigations 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectrum for CRV, PM and SD were depicted in fig. 2 (a-d). The 
characteristic shoulders of CRV were traced at 3342 cm-1 (N-H 
stretching), 3063 cm-1(C-H aromatic),2919 cm-1and 2989 cm-1(C-H 
aliphatic stretching), 1597 cm-1(C=C aromatic) and 1254 cm-1
The spectra of tartaric acid PM indicated that all the characteristic 
bands of drug and the polymer appear except the disappearance of 
the carbonyl group band of tartaric acid which may be due to the 
intermolecular hydrogen bond with N-Hand O-H. This reflected 




The spectra of tartaric acid SD indicated the appearance of new 
peak at 1601 cm-1
 
due to interaction between COOH of polymer 
and OH of drug lead to formation C=C with elimination of molecule 
of water, the disappearance of O-H band and C=O band of the 
polymer and N-H band of the drug which may be due to the 
intermolecular hydrogen bond between them. This reflected that 
there were significant interactions between the drug and the 
polymer. 
 
Fig. 2: FTIR spectra of CRV-tartaric acid systems. a) CRV alone, b) Pure tartaric acid, c) CRV-tartaric acid PM, d) CRV-tartaric acid SD 
 
Differential scanning calorimetry (DSC) 
In order to get evidence on the possible interaction between CRV 
and the investigated carrier (tartaric acid), DSC studies were 
performed. The DSC thermograms are shown in fig. 3. DSC curves of 
pure CRV exhibited a sharp endothermic peak at 113 o
The DSC thermogram of the CRV-tartaric acid physical mixture 
showed CRV two endothermic peaks, one at the same position of 
pure CRA but with decreased intensity and another at 162
C, which is 
corresponding to its melting point. 
The DSC thermogram of CRV–tartaric acid SD showed new 
endothermic peaks at temperatures different from that of pure drug 
and the carrier. This result indicated the interaction of the two 
components without miscibility, thus proving formation of an 
amorphous solid suspension. 
o
In DSC, changes in the melting endotherm of the drug and single Tg 
at a temperature between Tg values of both components is evidence 
for the formation of a miscible system (18). SDs can thus be 
classified as an amorphous solution (with single Tg), amorphous 
suspension (two Tgs) or crystalline suspension (Tg and melting 
event) [26, 33]. 
C due to 
the fusion of the carrier.  
This result indicated that some of CRV powder might be still in 
crystalline state, and this reflected the immiscibility of the two 
components, thus proving formation of an amorphous solid 
suspension [19]. This result is in agreement with Shamma RN et al., 
2013 [19]. 
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Fig. 3: DSC spectra of CRV–tartaric acid systems, a) CRV alone, b) Pure tartaric acid, c) CRV–tartaric acid PM, d) CRV–tartaric acid SD 
 
X-ray diffraction 
The x-ray diffraction patterns of CRV and tartaric acid PMs and SDs 
were illustrated in fig. 4. CRV was a powder with characteristic 
diffraction peaks at 2θ of 13.62o, 17.46o and 18.56o; 
In the case of untreated tartaric acid, there were peaks at 19.23
in addition, there 
were some other peaks of lower intensity. 
o, 
21.29o and 36.28o
On the other hand, the diffraction pattern of tartaric acid solid 
dispersion showed a change in the 2θ and the intensity of the 
peaks of CRV and tartaric acid, thus indicating that there was an 
interaction between the drug and the carriers. These results 
were in line with our findings from DSC and FTIR analysis. . The diffraction pattern of the tartaric acid 
physical mixture showed the peaks for both CRV and the carrier, 
thus indicating that there was not a strong interaction between 
the drug and the carriers.  
 
 
Fig. 4: X-ray spectra of CRV–tartaric acid systems, a) CRV alone, b) Pure tartaric acid, c) CRV–tartaric acid PM, d) CRV–tartaric acid SD 
 
In vivo study 
The mean arterial blood pressure (MAP) values obtained after 
administration of plain CRV and the tested formulation are 
illustrated in table 5. The results showed a very highly significant 
difference between the tested formulation and the plain drug. 
CRV-tartaric acid SD showed a decrease in MAP of hypertensive rats 
to normal values for about 5 h and then increased in the sixth hour. 
On the other side, with the plain CRV in the same dose (12 mg/kg), 
the decrease in MAP was continued for only 2 h. The 
antihypertensive effect difference clearly demonstrated that 
tartaric acid solid dispersion causes a significant increase in the 
bioavailability of the pure CRV. This is matching with Sherif et 
al., 2013 [34], who stated that the solid dispersion causes an 
increase in the relative bioavailability of the plain Sulpiride by 
1.8 times.  
Also, Kalaiselvan et al., 2007 [35], reported that ternary 
inclusion complex (prepared by using albendazole, 
hydroxypropyl-beta-cyclodextrin and L-tartaric acid at 1:1:1 
molar ratio) showed a bioavailability enhancement for 
albendazole by 3.2 fold increase compared to a commercial 
suspension. 
Statistical analysis of CRV from different formulations showed 
that the drop of MAP between the third and the end of the six 
hours after administration of CRV solid dispersions was highly 
significantly lowered compared to that obtained after oral 
suspension of the plain drug (all results showed P value less 
than 0.001). 
 
Ayoub et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 193-199 
  
198 
Table 5: Mean arterial blood pressure of different CRV formulations 
P value Group 3 Tartaric acid SD Group 2 CRV alone Group 1 control  
P>0.05 138.3±6.01 127.2±15.12 132.1±5.45 0 h 
P>0.05 111.7±16.41 109.4±12.5 131.1±4.8 0.5 h 
P>0.05 102.2±12.61 94.44±6.94 128.9±7.69 1 h 
P>0.05 72.22±8.39 79.33±2.4 130.9±2.3 2 h 
P<0.001 *** 64.55±8.69 111±9.76 137.8±1.92 3 h 
P<0.001 *** 53.33±5 121.2±4.5 135.0±5.77 4 h 
P<0.001 *** 44.44±5.09 119.2±0.84 133.9±8.66 5 h 
P<0.001 *** 80.00±10.93 127.8±6.73 135.6±7.7 6 h 
The results expressed as MAP±S. D (n=3). 
 
CONCLUSION 
This study demonstrated the ability of SDs prepared from (PEG) 
4000, (PVP) K30 and tartaric acid to enhance the solubility and 
dissolution of CRV. Tartaric acid can be considered as a 
promising carrier for improving the solubility, dissolution and 
oral bioavailability of CRV as SDs compared to pure CRV. This 
effect can be explained by FTIR, DSC and XRD diffraction which 
clarified the physical state of CRV and tartaric acid in the sample. 
The amorphous solid suspension was obtained in which the 
contribution of the tartaric acid carrier was concentration 
dependent. 
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